Tectonic Therapeutic
TECX | NASDAQ
$20.98
-$0.16 (-0.76%)
At close: Nov 16, 2026, 4:00 PM ET
$20.98
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Tectonic Therapeutic Company Profile
Company profile explainedCompany Profile
Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| Alise S. Reicin | President, Chief Executive Officer, Secretary & Director |
| Daniel Lochner | Chief Financial Officer |
| Anthony Muslin | Chief Development Officer |
| Geraldine Peters-Wiles | Senior Vice President of Human Resources |
| John Diener | Senior Vice President of Antibody Engineering & Protein Sciences |
| Marc Schwabish | Chief Business Officer |
| Marcella K. Ruddy | Chief Medical Officer |
| Mary West | Senior Vice President of Clinical Development Operations |
| Peter McNamara | Chief Scientific Officer |
| Washington Alves | Senior Vice President of Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 29, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 28, 2026 | 4 | Filing |
| Oct 02, 2026 | 4 | Filing |
| Oct 02, 2026 | 4 | Filing |
| Oct 02, 2026 | 4 | Filing |
| Oct 02, 2026 | 4 | Filing |
| Oct 02, 2026 | 4 | Filing |
| Sep 29, 2026 | 8-K | Current Report |
| Sep 08, 2026 | 4 | Filing |
| Sep 08, 2026 | 4 | Filing |
Tectonic Therapeutic
| Country | United States |
| IPO Date | Jun 21, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 60 |
| CEO | Alise S. Reicin |
Contact Details
490 Arsenal Way Watertown,
Massachusetts 02472 United States
Stock Details
| Ticker Symbol | TECX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001681087 |
| CUSIP Number | 878972108 |
| ISIN Number | US8789721086 |
| SIC Code | 2836 |
Add to Watchlist
Select watchlists to add or remove TECX